#Roommates, with U.S vaccination numbers continuously on the rise, one of the leading pharmaceutical companies supplying the vaccine, Pfizer, recently provided updated news regarding the treatment of COVID-19. During a recent interview, the CEO of Pfizer stated that a new COVID-19 anti-viral pill could be ready for distribution as early as this year.
@CNBC reports, Albert Bourla, the CEO of Pfizer stated that an anti-viral drug used to treat COVID-19 could be available by the end of the year. During a recent appearance on CNBC’s “Squawk Box,” Bourla was asked for updates regarding the anti-viral pill and he replied, “If all goes well and we implement the same speed that we did so far, and if regulators do the same and they are, I hope that by the end of the year.” On March 22nd, Pfizer previously revealed that its oral anti-viral drug, PF-07321332, had shown potential in treating COVID-19 patients as well as other coronavirus infections.
Meanwhile, researchers have confirmed that if Pfizer’s anti-viral drug is approved for use, it can be prescribed and taken at the first sign of a COVID-19 infection even if the patient is not hospitalized. The potential anti-viral drug would work by releasing inhibitors that bind to a virus and keep it from replicating.
As of now, the FDA has only approved remdesivir, for treatment against COVID-19 and is recommended for patients in a hospital who require supplemental oxygen.
Want updates directly in your text inbox? Hit us up at 917-722-8057 or click here to join!